MRC Technology and Keio University to collaborate on drug discovery
19 May London (UK) and Tokyo (Japan) MRC Technology and Keio University School of Medicine have signed a memorandum of understanding outlining their collaboration to identify promising antibody and small molecule research and translate them into early stage assets. By combining capabilities, the partnership aims to accelerate discovery to a stage where it is ready for clinical development by pharmaceutical companies and ultimately benefit patients.
MRC Technology, a medical research charity, aims to find treatments in areas of unmet patient needs. It offers commercialisation and intellectual property (IP) management skills and diagnostic and drug discovery expertise, specialising in small molecules and therapeutic antibodies.
Keio University is a modern institution found on ‘jitsugaku’ (science) based learning. It has developed expertise in a wide range of therapeutic areas, including cancer, cardiovascular and metabolic diseases.
MRC Technology has a similar agreement in place with Tokyo University.
19 May 2016
Patent protection for biotech/genetic engineering: report
Andrew Farquarson, Director, Technology Transfer, has been a member of the EU Commission’s Expert Group appointed in 2012 to advise on the Biotech Directive and patent protection for biotech/genetic engineering inventions.
Their report has now been published.
Medical related information are on page 127 (are/should stem cells, including human embryonic stem cells, be patentable ) and page 176 (should patents on nucleic acids be use-limited).
18 May 2016
MRC Technology, a medical research charity, has signed an agreement to review DEBRA Austria’s research portfolio, aiming to identify promising projects and results which could be suitable for translation into better treatments.
26 April 2016
MRC Technology, an independent life science medical research charity, has appointed Dr Les Hughes and Dr Mike Romanos to the board of trustees, with effect from 1 March 2016.
7 April 2016
MRC Technology and Institut Pasteur of Shanghai, Chinese Academy of Sciences (IPS-CAS) have signed a collaboration agreement to develop new therapeutic antibodies from research originating in China.
6 April 2016
Dementia Consortium welcomes MSD as a new partner in their global venture to accelerate drug discovery for neurodegenerative disease. MSD is the latest pharmaceutical company to join the Dementia Consortium – a £4.5 million charity-industry partnership between Alzheimer’s Research UK, MRC Technology and pharmaceutical companies Abbvie, Astex, Eisai and Lilly.
8 March 2016
New dementia drug discovery efforts get underway this month at the University of South Florida, thanks to £875,000 funding from the Dementia Consortium. The US team of academics will work with drug development experts at UK-based MRC Technology, to target the immune system in a bid to halt nerve cell damage.
1 March 2016
The Dementia Consortium has welcomed AbbVie as new pharmaceutical partner, joining medical research charity MRC Technology, Alzheimer’s Research UK, the UK’s leading dementia research charity, and pharmaceutical companies Astex, Eisai and Lilly.
16 February 2016
Partnership between MRC Technology and Alzheimer’s Association will focus on finding new ways to translate fundamental research findings into new medicines that manage and treat Alzheimer’s disease.
20 January 2016
MRC Technology has launched a Call for Diagnostics. It is seeking academic and industry collaborators to develop diagnostic tests in areas of unmet patient needs.
28 October 2015